{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:42:11Z","timestamp":1776361331783,"version":"3.51.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T00:00:00Z","timestamp":1530316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s10238-018-0515-4","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T04:56:48Z","timestamp":1530334608000},"page":"487-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"18","author":[{"given":"Kotaro","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-3725","authenticated-orcid":false,"given":"Hiroaki","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinao","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Haraguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,30]]},"reference":[{"key":"515_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0092-8674(00)81109-5","volume":"85","author":"M Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307\u201310.","journal-title":"Cell"},{"key":"515_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH672>3.0.CO;2-W","volume":"192","author":"I Itonaga","year":"2000","unstructured":"Itonaga I, Fujikawa Y, Sabokbar A, Murray DW, Athanasou NA. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol. 2000;192:97\u2013104.","journal-title":"J Pathol"},{"key":"515_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10067-011-1815-1","volume":"31","author":"G Guo","year":"2012","unstructured":"Guo G, Shang Y, Zhu G, Bao X, Xu S, Chen Y. The expression and distribution of immunomodulatory proteins B7-H1, B7-DC, B7-H3, and B7-H4 in rheumatoid synovium. Clin Rheumatol. 2012;31:271\u201381.","journal-title":"Clin Rheumatol"},{"key":"515_CR4","first-page":"1716","volume":"35","author":"S Yoshida","year":"2008","unstructured":"Yoshida S, Higuchi F, Ishibashi Y, et al. Downregulation of RCAS1 and upregulation of cytotoxic T cells affects synovial proliferation and apoptosis in rheumatoid arthritis. J Rheumatol. 2008;35:1716\u201322.","journal-title":"J Rheumatol"},{"key":"515_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1073\/pnas.89.2.549","volume":"89","author":"GM Griffiths","year":"1992","unstructured":"Griffiths GM, Alpert S, Lambert E, McGuire J, Weissman IL. Perforin and granzyme A expression identifying cytolytic lymphocytes in rheumatoid arthritis. Proc Natl Acad Sci USA. 1992;89:549\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"515_CR6","first-page":"265","volume":"38","author":"H Belfrage","year":"1994","unstructured":"Belfrage H, Bhiladvala P, Hedlund G, Dohlsten M, Kalland T. Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity. Cancer Immunol Immunother. 1994;38:265\u201371.","journal-title":"Cancer Immunol Immunother"},{"key":"515_CR7","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887\u201395.","journal-title":"EMBO J"},{"key":"515_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765\u201372.","journal-title":"Int Immunol"},{"key":"515_CR9","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1073\/pnas.231486598","volume":"98","author":"T Okazaki","year":"2001","unstructured":"Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA. 2001;98:13866\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"515_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141\u201351.","journal-title":"Immunity"},{"key":"515_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319\u201322.","journal-title":"Science"},{"key":"515_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365\u20139.","journal-title":"Nat Med"},{"key":"515_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261\u20138.","journal-title":"Nat Immunol"},{"key":"515_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203:883\u201395.","journal-title":"J Exp Med"},{"key":"515_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"515_CR16","first-page":"2156","volume":"32","author":"M Kobayashi","year":"2005","unstructured":"Kobayashi M, Kawano S, Hatachi S, et al. Enhanced expression of programmed death-1 (PD-1)\/PD-L1 in salivary glands of patients with Sj\u00f6gren\u2019s syndrome. J Rheumatol. 2005;32:2156\u201363.","journal-title":"J Rheumatol"},{"key":"515_CR17","doi-asserted-by":"publisher","first-page":"8844","DOI":"10.4049\/jimmunol.177.12.8844","volume":"177","author":"B Wan","year":"2006","unstructured":"Wan B, Nie H, Liu A, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177:8844\u201350.","journal-title":"J Immunol"},{"key":"515_CR18","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/art.27500","volume":"62","author":"AP Raptopoulou","year":"2010","unstructured":"Raptopoulou AP, Bertsias G, Makrygiannakis D, et al. The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870\u201380.","journal-title":"Arthritis Rheum"},{"key":"515_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/03009742.2013.823517","volume":"43","author":"SR Greisen","year":"2014","unstructured":"Greisen SR, Rasmussen TK, Stengaard-Pedersen K, et al. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol. 2014;43:101\u20138.","journal-title":"Scand J Rheumatol"},{"key":"515_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s10753-013-9718-8","volume":"37","author":"S Li","year":"2014","unstructured":"Li S, Liao W, Chen M, et al. Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis. Inflammation. 2014;37:116\u201321.","journal-title":"Inflammation"},{"key":"515_CR21","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"515_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2559.2006.02508.x","volume":"49","author":"V Krenn","year":"2006","unstructured":"Krenn V, Morawietz L, Burmester GR, et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology. 2006;49:358\u201364.","journal-title":"Histopathology"},{"key":"515_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3109\/03009742.2011.623137","volume":"41","author":"S Yoshida","year":"2012","unstructured":"Yoshida S, Arakawa F, Higuchi F, et al. Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scand J Rheumatol. 2012;41:170\u20139.","journal-title":"Scand J Rheumatol"},{"key":"515_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.autrev.2013.05.003","volume":"12","author":"E Gianchecchi","year":"2013","unstructured":"Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1\/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013;12:1091\u2013100.","journal-title":"Autoimmun Rev"},{"key":"515_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1084\/jem.20022235","volume":"198","author":"Y Iwai","year":"2003","unstructured":"Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med. 2003;198:39\u201350.","journal-title":"J Exp Med"},{"key":"515_CR26","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"515_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/art.20040","volume":"50","author":"SC Lin","year":"2004","unstructured":"Lin SC, Yen JH, Tsai JJ, et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum. 2004;50:770\u20135.","journal-title":"Arthritis Rheum"},{"key":"515_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492\u20139.","journal-title":"Nat Immunol"},{"key":"515_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"515_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/art.1780380115","volume":"38","author":"JJ Cush","year":"1995","unstructured":"Cush JJ, Splawski JB, Thomas R, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:96\u2013104.","journal-title":"Arthritis Rheum"},{"key":"515_CR31","first-page":"1874","volume":"29","author":"JM Anaya","year":"2002","unstructured":"Anaya JM, Correa PA, Herrera M, Eskdale J, Gallagher G. Interleukin 10 (IL-10) influences autoimmune response in primary Sj\u00f6gren\u2019s syndrome and is linked to IL-10 gene polymorphism. J Rheumatol. 2002;29:1874\u20136.","journal-title":"J Rheumatol"},{"key":"515_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10238-004-0049-9","volume":"4","author":"R Bertorello","year":"2004","unstructured":"Bertorello R, Cordone MP, Contini P, et al. Increased levels of interleukin-10 in saliva of Sj\u00f6gren\u2019s syndrome patients. Correlation with disease activity. Clin Exp Med. 2004;4:148\u201351.","journal-title":"Clin Exp Med"},{"key":"515_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/rheumatology\/34.3.226","volume":"34","author":"SM Brookes","year":"1995","unstructured":"Brookes SM, Price EJ, Venables PJ, Maini RN. Interferon-gamma and epithelial cell activation in Sj\u00f6gren\u2019s syndrome. Br J Rheumatol. 1995;34:226\u201331.","journal-title":"Br J Rheumatol"},{"key":"515_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/rheumatology\/35.1.24","volume":"35","author":"RJ Dolhain","year":"1996","unstructured":"Dolhain RJ, ter Haar NT, Hoefakker S, et al. Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Br J Rheumatol. 1996;35:24\u201332.","journal-title":"Br J Rheumatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-018-0515-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-018-0515-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-018-0515-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T21:19:02Z","timestamp":1720387142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-018-0515-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,30]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1007\/s10238-018-0515-4","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,30]]},"assertion":[{"value":"31 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}